Dimerix Receives FDA feedback for DMX-200 trial
- Dimerix (DXB) moves a step closer towards phase three clinical trials for its DMX-200 candidate following a guidance meeting with the US Food and Drug Administration
- The FDA is said to be “broadly supportive” of its planned trial and DXB has subsequently begun seeking clinical sites
- Broadly, The company said the feedback has given the company confidence in the study design and appropriate endpoints
- The company Chief Executive Officer and Managing Director Dr Nina Webster commented on the meeting outcome
- In addition, The company said the feedback was consistent with advice receive from the European Medicines Agency in June
- The company shares are up 2.13 percent and trading at 24 cents at 4:38 pm AEST
